Página principal > Artículos > Resultados de la búsqueda: Puig Sanz, Lluís

Artículos

  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Artículos Encontrados 95 registros  inicioanterior80 - 89siguiente  ir al registro: La búsqueda tardó 0.00 segundos. 
80.
13 p, 3.0 MB Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis : pooled analyses of two randomized phase clinical trials (re 1 and re 2) through 148 weeks / Reich, Kristian (Dermatologikum Berlin) ; Warren, R. B. (The University of Manchester. Manchester NIHR Biomedical Research Centre. Salford Royal NHS Foundation Trust) ; Iversen, Lars (Aarhus University Hospital (Aarhus, Dinamarca)) ; Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ; Pau-Charles, I. (Almirall R&D) ; Igarashi, A. (NTT Medical Center Tokyo) ; Ohtsuki, M. (Jichi Medical University) ; Falqués, M. (Almirall R&D) ; Harmut, M. (Almirall R&D) ; Rozzo, S. (Sun Pharmaceuticals) ; Lebwohl, M. G. (Icahn School of Medicine at Mount Sinai) ; Cantrell, W. (University of Alabama at Birmingham) ; Blauvelt, Andrew (Oregon Medical Research Center) ; Thaçi, Diamant (University of Lübeck) ; Universitat Autònoma de Barcelona
Tildrakizumab is a specific anti-interleukin-23p19 monoclonal antibody approved for the treatment of plaque psoriasis. To evaluate the long-term efficacy and safety of tildrakizumab treatment for patients with moderate-to-severe psoriasis for up to 148 weeks. [...]
2019 - 10.1111/bjd.18232
British journal of dermatology, Vol. 182 (july 2019) , p. 605-617  
Registro completo - Creative Commons
81.
8 p, 338.9 KB Quantification of Malassezia pachydermatis by real-time PCR in swabs from the external ear canal of dogs / Puig Sanz, Lluís. (Universitat Autònoma de Barcelona. Departament de Sanitat i d'Anatomia Animals) ; Castellá, Gemma (Universitat Autònoma de Barcelona. Departament de Sanitat i d'Anatomia Animals) ; Cabañes Sáenz, Francisco Javier (Universitat Autònoma de Barcelona. Departament de Sanitat i d'Anatomia Animals)
Malassezia pachydermatis is part of the normal microbiota of canine skin and external ear canal, and is also associated with otitis externa in dogs. Laboratory detection of Malassezia otitis relies on the presence of elevated numbers of the yeast on cytologic examination of otic exudate. [...]
2019 - 10.1177/1040638719840686
Journal of Veterinary Diagnostic Investigation, Vol. 31 Núm. 3 (january 2019) , p. 440-447  
Registro completo - Creative Commons
82.
9 p, 453.9 KB Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis : pooled analysis across six clinical trials / Strober, Bruce (Probity Medical Research) ; Gottlieb, Alice B (New York Medical College at Metropolitan Hospital) ; van de Kerkhof, P. C. M. (Radboud University Nijmegen Medical Centre) ; Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ; Bachelez, Hervé (Sorbonne Paris Cité Université Paris Diderot. Assistance Publique-Hôpitaux de Paris. Service de Dermatologie. Hôpital Saint-Louis) ; Chouela, E. (Universidad de Buenos Aires) ; Imafuku, S. (Department of Dermatology. Faculty of Medicine. Fukuoka University) ; Thaçi, Diamant (Universitätsklinikum Schleswig-Holstein (Alemanya)) ; Tan, H. (Pfizer Inc.) ; Valdez, H. (Pfizer Inc.) ; Gupta, P. (Pfizer Inc.) ; Kaur, M. (Pfizer Inc.) ; Frajzyngier, V. (Pfizer Inc.) ; Wolk, R. (Pfizer Inc.) ; Universitat Autònoma de Barcelona
Background: Although existing psoriasis treatments are effective and well tolerated in many patients, there is still a need for new effective targeted treatment options. Tofacitinib is an oral Janus kinase inhibitor that has been investigated in patients with moderate-to-severe chronic plaque psoriasis. [...]
2019 - 10.1111/bjd.17149
British journal of dermatology, Vol. 180 Núm. 1 (january 2019) , p. 67-75  
Registro completo - Creative Commons
83.
5 p, 332.3 KB Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment : Results from the CLEAR study / Thaçi, Diamant (Research Institute and Comprehensive Center for Inflammation Medicine. University of Luebeck) ; Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ; Reich, Kristian (Dermatologikum Berlin and SCIderm Research Institute) ; Tsai, T. F. (National Taiwan University Hospital (Taipei, Taiwan)) ; Tyring, S. (University of Texas Health Science Center and Center for Clinical Studies) ; Kingo, Külli (Tartu University Hospital (Tartu, Estònia)) ; Ziv, M. (Emek Medical Center) ; Pinter, A. (Department of Dermatology. University of Frankfurt) ; Vender, Ronald (Venderm Innovations in Psoriasis) ; Lacombe, A. (Novartis Pharma AG) ; Xia, Shang (Novartis Beijing Novartis Pharma Co Ltd) ; Bhosekar, V. (Novartis Healthcare Pvt Ltd) ; Gilloteau, I. (Novartis Pharma AG) ; Guana, A. (Novartis Pharmaceuticals Corporation) ; Blauvelt, Andrew (Oregon Medical Research Center) ; Universitat Autònoma de Barcelona
2019 - 10.1016/j.jaad.2019.04.045
Journal of the American Academy of Dermatology, Vol. 81 Núm. 6 (december 2019) , p. 1405-1409  
Registro completo - Creative Commons
84.
1 p, 320.3 KB Correction to : Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) / Blauvelt, Andrew (SW Locust St., Suite G, Portland, OR 97223 USA) ; Papp, Kim A. (Waterloo, Canada) ; Griffiths, Christopher E. M. (Manchester, UK) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Weisman, Jamie (Medical Dermatology Specialists, Inc., Atlanta, GA USA) ; Dutronc, Yves (Indianapolis, IN USA) ; Kerr, Lisa Farmer (Indianapolis, IN USA) ; Ilo, Dapo (Indianapolis, IN USA) ; Mallbris, Lotus (Indianapolis, IN USA) ; Augustin, Matthias (University Medical Center Hamburg-Eppendorf) ; Universitat Autònoma de Barcelona
2018 - 10.1007/s40257-018-0353-x
American Journal of Clinical Dermatology, Vol. 19 (march 2018) , p. 457  
Registro completo - Creative Commons
85.
8 p, 420.3 KB Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders : a Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) / Blauvelt, Andrew (SW Locust St., Suite G, Portland, USA) ; Papp, Kim A. (Waterloo, Canada) ; Griffiths, Christopher E. M. (Manchester, UK) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Weisman, Jamie (Medical Dermatology Specialists, Inc., Atlanta, GA USA) ; Dutronc, Yves (Indianapolis, IN USA) ; Kerr, Lisa Farmer (Indianapolis, IN USA) ; Ilo, Dapo (Indianapolis, IN USA) ; Mallbris, Lotus (Indianapolis, IN USA) ; Augustin, Matthias (University Medical Center Hamburg-Eppendorf) ; Universitat Autònoma de Barcelona
Patients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic, such as ixekizumab, a high affinity monoclonal antibody that selectively targets interleukin (IL)-17A. [...]
2017 - 10.1007/s40257-016-0246-9
American Journal of Clinical Dermatology, Vol. 18 (january 2017) , p. 273-280  
Registro completo - Creative Commons
86.
19 p, 292.5 KB Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis / Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
There is solid epidemiologic evidence linking psoriasis and psoriatic arthritis (PsA) to cardiovascular risk factors and an increased risk of developing cardiovascular disease. Chronic inflammation, with shared pathways and cytokines common to metabolic syndrome, atherosclerosis and psoriasis, might provide the basis for the cardiovascular and metabolic comorbidities of psoriasis and PsA. [...]
2017 - 10.3390/ijms19010058
International journal of molecular sciences, Vol. 19 (december 2017)  
Registro completo - Creative Commons
87.
7 p, 226.4 KB Improving patient outcomes in psoriasis : strategies to ensure treatment adherence / Yélamos, Oriol (Institut d'Investigació Biomèdica Sant Pau) ; Ros, Sandra (Institut d'Investigació Biomèdica Sant Pau) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Psoriasis is a frequent inflammatory disease with a chronic and relapsing course. Therefore, patients with psoriasis are likely to undergo different treatments for long periods of time. Traditionally, therapies used in psoriasis have been associated with poor levels of adherence due to the complexity of the regimens and the poor results obtained with the topical therapies. [...]
2015 - 10.2147/PTT.S54070
Psoriasis (Auckland, N.Z.), Vol. 5 (july 2015) , p. 109-115  
Registro completo - Creative Commons
88.
11 p, 1.5 MB The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis / Girolomoni, Giampiero (University of Verona) ; Strohal, Robert (Federal Academic Teaching Hospital of Feldkirch) ; Puig Sanz, Lluís (Universitat Autònoma de Barcelona) ; Bachelez, Hervé (Institut Imagine (Paris, França)) ; Barker, Jonathan (King's College London) ; Boehncke, Wolf-Henning (University of Geneva) ; Prinz, Joerg (University of Munich)
Psoriasis is a chronic, immune-mediated disease affecting more than 100 million people worldwide and up to 2. 2% of the population. The aetiology of psoriasis is thought to originate from an interplay of genetic, environmental, infectious and lifestyle factors. [...]
2017 - 10.1111/jdv.14433
Journal of the European Academy of Dermatology and Venereology, Vol. 31, Issue 10 (October 2017) , p. 1616-1626  
Registro completo - Creative Commons
89.
1 p, 338.7 KB Erratum to : Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials / Adsit, Sandra (TCR Medical Corporation) ; Zaldivar, Enrique Rivas (Dermos, Guatemala City, Guatemala) ; Sofen, Howard (Los Angeles, CA USA) ; Dei-Cas, Ignacio (Halitus, Buenos Aires, Argentina) ; Maldonado-García, César (Centro Dermatológico "Dr. Ladislao de la Pascua", Mexico City, Mexico) ; Peñaranda, Elkin O. (Riesgo de Fractura S.A., Bogota, Colombia) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Meng, Xiangyi (East Hanover, NJ USA) ; Fox, Todd (Basel, Switzerland) ; Guana, Adriana (East Hanover, NJ USA) ; Universitat Autònoma de Barcelona
Introduction: There is little evidence available on the efficacy and safety of biologic therapies for the treatment of psoriasis in Hispanic patients. Secukinumab is demonstrated to be highly effective for clearing psoriasis. [...]
2017 - 10.1007/s12325-017-0563-2
Advances in Therapy, Vol. 34 (june 2017) , p. 1772  
Registro completo - Creative Commons

Artículos : Encontrados 95 registros   inicioanterior80 - 89siguiente  ir al registro:
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos